Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1

Galina Semenova, Dina S. Stepanova, Sergey M. Deyev, Jonathan Chernoff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The variable manifestation of phenotypes that occur in patients with neurofibromatosis type 1 (NF1) includes benign and malignant neurocutaneous tumors for which no adequate treatment exists. Cell-based screening of known bioactive compounds library identified the protein phosphatase 2A (PP2A) inhibitor Cantharidin and the L-type calcium channel blocker Nifedipine as potential candidates for NF1 pharmacotherapy. Validation of screening results using human NF1-associated malignant peripheral nerve sheath tumor (MPNST) cells showed that Cantharidin effectively impeded MPNST cell growth, while Nifedipine treatment significantly decreased local tumor growth in an MPNST xenograft animal model. These data suggest that inhibitors of PP2A, as well as calcium channel blockers, might be used in broader MPNST preclinical studies as single agents or in combinatorial therapeutic strategies.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalBiochimie
Volume135
DOIs
Publication statusPublished - 1 Apr 2017
Externally publishedYes

Fingerprint

Drug therapy
Neurofibromatosis 1
Neurilemmoma
Tumors
Screening
Cantharidin
Throughput
Drug Therapy
Protein Phosphatase 2
Calcium Channel Blockers
Nifedipine
L-Type Calcium Channels
Growth
Heterografts
Libraries
Neoplasms
Therapeutics
Animal Models
Cell growth
Phenotype

Keywords

  • Cantharidin
  • Chemical screening
  • Neurofibromatosis type 1
  • Nifedipine

ASJC Scopus subject areas

  • Biochemistry

Cite this

Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. / Semenova, Galina; Stepanova, Dina S.; Deyev, Sergey M.; Chernoff, Jonathan.

In: Biochimie, Vol. 135, 01.04.2017, p. 1-5.

Research output: Contribution to journalArticle

@article{987e30b2a81041289771df0da7672abc,
title = "Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1",
abstract = "The variable manifestation of phenotypes that occur in patients with neurofibromatosis type 1 (NF1) includes benign and malignant neurocutaneous tumors for which no adequate treatment exists. Cell-based screening of known bioactive compounds library identified the protein phosphatase 2A (PP2A) inhibitor Cantharidin and the L-type calcium channel blocker Nifedipine as potential candidates for NF1 pharmacotherapy. Validation of screening results using human NF1-associated malignant peripheral nerve sheath tumor (MPNST) cells showed that Cantharidin effectively impeded MPNST cell growth, while Nifedipine treatment significantly decreased local tumor growth in an MPNST xenograft animal model. These data suggest that inhibitors of PP2A, as well as calcium channel blockers, might be used in broader MPNST preclinical studies as single agents or in combinatorial therapeutic strategies.",
keywords = "Cantharidin, Chemical screening, Neurofibromatosis type 1, Nifedipine",
author = "Galina Semenova and Stepanova, {Dina S.} and Deyev, {Sergey M.} and Jonathan Chernoff",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.biochi.2017.01.001",
language = "English",
volume = "135",
pages = "1--5",
journal = "Biochimie",
issn = "0300-9084",
publisher = "Elsevier",

}

TY - JOUR

T1 - Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1

AU - Semenova, Galina

AU - Stepanova, Dina S.

AU - Deyev, Sergey M.

AU - Chernoff, Jonathan

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The variable manifestation of phenotypes that occur in patients with neurofibromatosis type 1 (NF1) includes benign and malignant neurocutaneous tumors for which no adequate treatment exists. Cell-based screening of known bioactive compounds library identified the protein phosphatase 2A (PP2A) inhibitor Cantharidin and the L-type calcium channel blocker Nifedipine as potential candidates for NF1 pharmacotherapy. Validation of screening results using human NF1-associated malignant peripheral nerve sheath tumor (MPNST) cells showed that Cantharidin effectively impeded MPNST cell growth, while Nifedipine treatment significantly decreased local tumor growth in an MPNST xenograft animal model. These data suggest that inhibitors of PP2A, as well as calcium channel blockers, might be used in broader MPNST preclinical studies as single agents or in combinatorial therapeutic strategies.

AB - The variable manifestation of phenotypes that occur in patients with neurofibromatosis type 1 (NF1) includes benign and malignant neurocutaneous tumors for which no adequate treatment exists. Cell-based screening of known bioactive compounds library identified the protein phosphatase 2A (PP2A) inhibitor Cantharidin and the L-type calcium channel blocker Nifedipine as potential candidates for NF1 pharmacotherapy. Validation of screening results using human NF1-associated malignant peripheral nerve sheath tumor (MPNST) cells showed that Cantharidin effectively impeded MPNST cell growth, while Nifedipine treatment significantly decreased local tumor growth in an MPNST xenograft animal model. These data suggest that inhibitors of PP2A, as well as calcium channel blockers, might be used in broader MPNST preclinical studies as single agents or in combinatorial therapeutic strategies.

KW - Cantharidin

KW - Chemical screening

KW - Neurofibromatosis type 1

KW - Nifedipine

UR - http://www.scopus.com/inward/record.url?scp=85009224892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009224892&partnerID=8YFLogxK

U2 - 10.1016/j.biochi.2017.01.001

DO - 10.1016/j.biochi.2017.01.001

M3 - Article

VL - 135

SP - 1

EP - 5

JO - Biochimie

JF - Biochimie

SN - 0300-9084

ER -